PHAXIAM Therapeutics S.A. Overview

PHAXIAM Therapeutics S.A. Research & Development

Research & Development expenses for PHXM.

Quarterly R&D Expenses

$7.01M

↓ 1591.49% YoY

As of Dec 31, 2023

Annual R&D Expenses (TTM)

$9.87M

↓ 67.92% YoY

Trailing 12 months ending Dec 31, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin